You have 9 free searches left this month | for more free features.

City

Beijing (1)

Condition

Primary Membranous Nephropathy (2)

Neuromyelitis Optica Spectrum Disorder (1)

Systemic Lupus Erythematosus (1)

Overall Status

Not yet recruiting (3)

Recruiting (1)

Sign in for free

Phase

phase 3 (2)

phase 1/phase 2 (1)

phase 2/phase 3 (1)

Sponsor

Beijing Mabworks Biotech Co., Ltd. (4)

Collaborator

Intervention

mil62 (4)

cyclosporine (2)

placebo (2)

Study Documents

Intervention Type

drug (4)

other (1)

Funder Type

Industry (4)

Study Type

Interventional (4)

mil62

Showing 1 - 4 of 4

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Primary Membranous Nephropathy Trial (MIL62, Cyclosporine)

Not yet recruiting

Primary Membranous Nephropathy

MIL62
Cyclosporine

(no location specified)

May 16, 2023

Systemic Lupus Erythematosus Trial (MIL62, )

Not yet recruiting

Systemic Lupus Erythematosus

MIL62
placebo

(no location specified)

Mar 21, 2023

Neuromyelitis Optica Spectrum Disorder Trial in Beijing (MIL62, Placebo)

Not yet recruiting

Neuromyelitis Optica Spectrum Disorder

MIL62
Placebo

(no location specified)

May 26, 2022

Primary Membranous Nephropathy Trial in Beijing (MIL62, Cyclosporine)

Recruiting

Primary Membranous Nephropathy

MIL62
Cyclosporine

Beijing, Beijing, China

Peking University First Hospital

May 26, 2022